We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
CohBar and the US National Institute of Allergy and Infectious Diseases (NIAID) have signed a non-clinical evaluation agreement (NCEA) to analyse CB5064 Analogs for treating Covid-19 related Acute Respiratory Distress Syndrome (ARDS).